Wednesday, February 22, 2012

Site Search

Archive for June, 2011

Salmonella infections rise in US: study

WASHINGTON — US cases of salmonella have risen 10 percent in recent years, while other food-borne illnesses caused by E. coli and related bacteria have declined dramatically, the US government said on Tuesday.

Even as Germany grapples with a mysterious E. coli outbreak that has killed two dozen people, the United States has cut similar infections from serious Shiga toxin-producing E.coli O157 by nearly half in the past 15 years.

And overall rates of food-borne infection have declined by 23 percent in that time period, said the Centers for Disease Control and Prevention.

But Salmonella, which can infect eggs, poultry, meat, vegetables or processed foods, remained the most common cause of food-borne illness and a stubborn foe.

“Although food-borne infections have decreased by nearly one-fourth in the past 15 years, more than one million people in this country become ill from Salmonella each year,” said CDC director Thomas Frieden.

“Continued investments are essential to detect, investigate, and stop outbreaks promptly in order to protect our food supply.”

Last year, Salmonella caused 54 percent of total hospitalizations (2,300 of the total 4,200 hospitalizations) for food illness and 43 percent of all such deaths (29 of the total 68 deaths), the CDC data said.

“The incidence of Salmonella infection in 2010 was not significantly different than during 1996-1998 but was significantly higher than during 2006-2008,” a 10 percent increase, it noted.

Salmonella incurs $365 million in direct medical costs each year in the United States, the CDC said.

Pathogens included in the overall reduced level of infections compared to 1996-1998 included campylobacter, E. coli STEC O157, listeria, and yersinia.

However, vibrio infection rates, most often seen in raw seafood and shellfish, were 115 percent higher than in 1996-1998, and 39 percent higher than in 2006-2008.

“People who want to reduce their risk of food-borne illness should assume raw chicken and other meat carry bacteria that can cause illness and should not allow them to contaminate surfaces and other foods, such as produce,” the CDC said.

Source: http://www.google.com/hostednews/afp/article/ALeqM5g0MQC8xasEjpzHNuoAvpiXaPOLPg?docId=CNG.e1b00e99c52eeaad1951ccf575852c55.251

Blood pressure drugs not linked to cancer risk, says FDA

A type of blood pressure-lowering medication known as angiotensin receptor blockers won’t increase a patient’s risk for cancer, the Food and Drug Administration said this week. So those taking the drugs for high blood pressure can just…relax.

Concern about the drugs’ possible link to cancer risk arose last year after an analysis of several studies suggested that angiotensin receptor blockers, or ARBs, might be associated with a slightly increased risk of cancer.

But the FDA’s own research found no such connection, the agency said in an announcement Thursday:

“This analysis included 31 trials and approximately 156,000 patients, far more than the approximately 62,000 in the published analysis. FDA’s more comprehensive meta-analysis did not show an increased risk of cancer in the patients taking an ARB medication.”

Such medications include: losartan (Cozaar), olmesartan (Benicar) and valsartan (Diovan). The drugs lower blood pressure by blocking the effects of angiotensin II, a chemical that narrows vessels.

There are other ways to lower blood pressure. Beta blockers, ACE inhibitors, calcium channel blockers and renin inhibitors all lower pressure through different mechanisms, according to a blood pressure guide from the Mayo Clinic.

Of course, lifestyle changes can sometimes obviate the need for blood pressure-lowering drugs. Not smoking, eating a low-sodium diet, exercising regularly and limiting alcohol can all help control blood pressure — and there was never any concern about their cancer risk.

Source: http://www.latimes.com/health/boostershots/la-heb-fda-arb-cancer-20110603,0,4559969.story?track=rss

Bristol, Roche team up on melanoma study

(Reuters) – Bristol-Myers Squibb and Roche Holding AG said on Thursday they would evaluate their respective cancer drugs as a potential combination therapy for metastatic melanoma.

The collaboration involves a Phase I/II study with Bristol’s recently approved Yervoy and Roche’s experimental drug, vemurafenib, to determine the safety and efficacy of the combination in treating the deadliest form of skin cancer.

The announcement comes as the American Society of Clinical Oncology meeting begins this weekend in Chicago, where emerging treatments for melanoma will be in the spotlight.

Among the most eagerly anticipated studies being presented at the ASCO meeting will be a Phase III trial intended to show that vemurafenib extended the lives of patients with advanced melanoma, and another study comparing Yervoy to chemotherapy in patients with the fatal disease.

Yervoy won U.S. approval in March for patients with inoperable or metastatic melanoma, making it the first new treatment option in many years for patients for whom there was little hope and virtually no effective medicines.

Roche and Japanese drugmaker Daiichi Sankyo Co recently submitted U.S. and European applications seeking approval for vemurafenib. The drug was developed by Roche’s Genentech unit and Plexxikon, which was recently acquired by Daiichi.

Vemurafenib, a so-called BRAF inhibitor, is designed to selectively target and inhibit a mutated form of the BRAF protein found in about half of all cases of melanoma. The combination study with Yervoy will be in patients with BRAF-mutated metastatic melanoma, Roche said.

Roche is also developing a combination diagnostic to help identify those patients with the BRAF mutation who are likely to benefit from vemurafenib.

“We are entering a new era for melanoma, and are committed to studying exciting combinations with investigational medicines in our own pipeline,” Roche Chief Medical Officer Hal Barron said in a statement.

If proven effective and approved the Yervoy-vemurafenib combination would be an extremely expensive treatment option that could meet with reimbursement resistance from government programs and health insurers.

Bristol priced a four-infusion course of Yervoy at about $120,000. Vemurafenib will likely also command premium pricing if it too demonstrates an ability to help patients live longer.

More than 70,000 people in the United States and 160,000 worldwide are diagnosed with melanoma each year, according to the American Cancer Society. The five-year survival rate for the aggressive cancer is just 15 percent.

Source: http://www.reuters.com/article/2011/06/02/us-bristol-roche-melanoma-idUSTRE75151W20110602

Smelly chemicals confuse mosquitoes

Chemicals which interfere with a mosquito’s ability to sniff out humans have been developed by US researchers, according to research in Nature.

It is hoped they could be used to develop the next generation of mosquito traps and repellents.

A UK expert said the discovery could be a “major step forward” if the chemicals were safe and cheap.

Female mosquitoes use carbon dioxide in people’s exhaled breath to find their next meal.

They can detect minute changes in the concentration of the gas and track it back to a human breath.

This knowledge is already used in carbon dioxide traps, but requires dry ice or gas cylinders – which mean they are rarely used in developing countries.

Researchers have been looking for chemicals which can disrupt or confuse a mosquito’s carbon dioxide sense.

Deception

Scientists at the University of California, Riverside, tested smelly chemicals on three species of mosquito: Anopheles gambiae, which spreads malaria; Culex quinquefasciatus, which spreads filariasis and West Nile virus; and Aedes aegypti which spreads dengue and yellow fever.

Between them these insects are thought to spread disease to half a billion people each year and cause millions of deaths.

The researchers identified three groups of chemicals, which disrupt a mosquito’s carbon dioxide receptors.

One mimicked carbon dioxide and could be used as bait in insect traps, another prevented the mosquito from detecting carbon dioxide and the last group tricked the mosquito’s brain into thinking it was surrounded by huge quantities of the gas – so it could not pick which way to go.

Professor Anandasankar Ray, from the University of California, Riverside, said: “These chemicals offer powerful advantages as potential tools for reducing mosquito-human contact, and can lead to the development of new generations of insect repellents and lures.

“The identification of such odour molecules, which can work even at low concentrations, and are therefore economical, could be enormously effective in compromising the ability of mosquitoes to seek humans, thus helping control the spread of mosquito-borne diseases.”

Carbon dioxide is not the only way mosquitoes can find their dinner however, as the smell of human sweat and skin can also be used.

Dr James Logan, from the London School of Hygiene and Tropical Medicine, said: “Whilst this is an exciting study, the authors are yet to show that the chemicals are capable of protecting a human being from being bitten.

“Although carbon dioxide is an important cue for mosquitoes, we know that mosquitoes respond differently to a trap releasing carbon dioxide than to a real human being, which releases a complex mixture of many attractive chemicals, heat, visual cues and moisture.

“The key question is – do the ‘response modifying odours’ actually protect a human being?”

The chemicals also need to be used at high concentrations, which could be hazardous to human health. The researchers say their next step is to develop safer chemicals.

Dr Nikolai Windbichler, from Imperial College London, said work needed to be done to ensure they were safe and could be produced at low cost.

He added: “These compounds have novel and desirable properties because they can confuse the mosquitoes’ host seeking behaviour even when the substances are no longer present or the mosquitoes have left the area of application.

“This, if realised, could be a major step forward and could protect large groups of people or large areas, something that is not currently feasible with existing repellents.”

Mark Stopfer, from the US National Institutes of Health, said the study offered “a promising line of defence.”

Source: http://www.bbc.co.uk/news/health-13614781